Effect of dexmedetomidine on the level of parathyroid hormone in arteriovenous fistula operation under local anesthesia

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006854

Enrollment

Unknown

Registered

2015-07-31

Start date

2015-07-27

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elevated parathyroid hormone levels in patients with chronic renal failure

Interventions

Dexmedetomidine Group:Continuous intravenous infusion

Midazolam group:Continuous intravenous infusion

Sodium chloride injection group:Continuous intravenous infusion

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. aged between 18-60 years; ASA grade 2-3; 2. no alcohol and drug abuse history; 3. no obesity (BMI 30), no other endocrine diseases; 4. the first time to accept the operation of arteriovenous fistula operation; 5. the recent not taken to affect the level of parathyroid hormone drugs; 6. in addition to diabetes, no other endocrine diseases.

Exclusion criteria

Exclusion criteria: 1. sinus tachycardia; 2. atrioventricular block; 3. severe heart disease; 4. there are chronic drug addicts; 5. taking the effect of parathyroid hormone levels of drugs; 6. hearing and memory disorders.

Design outcomes

Primary

Measure	Time frame
Parathyroid hormone;Calcium ion;	—

Secondary

Measure	Time frame
Sodium ion;Potassium ion;Magnesium ion;Blood glucose;Blood pressure;Heart rate;Pulse oxygen saturation;Sedation score;PH;	—

Countries

China

Contacts

Public ContactChenshun Gao

godson1234567@163.com+86 13941142232

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026